Brief: Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis
13/03/2026 13:13
March 13 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS: IDMC RECOMMENDS DISCONTINUATION OF TACTI-004 PHASE III TRIAL AFTER INTERIM FUTILITY ANALYSIS IMMUTEP TO HALT ENROLMENT AND WIND DOWN TACTI-004 PHASE III STUDY Source text: ID:nBSE8hmsTG Further company coverage: REDY.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Dr. Reddy's Laboratories
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Dr Reddy's beats quarterly profit estimate on India market lift (updated)
India's Dr Reddy's beats quarterly profit estimate
Brief: Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption